Van-Far Discusses “F” Policy, MSHSAA
Van-far discusses “F” policy, MSHSAA
Filed under: Drug Treatment Washington D.C.
A quote concerning student drug testing has yet to be received. … High School Students of the Month Ryan Nelson and Sheridan Cole presented the board with their recent FFA trip to Washington D.C. for the Washington Leadership Conference (WLC).
Read more on The Vandalia Leader
The Zacks Analyst Blog Highlights: McGraw-Hill, Moody's, Gilead Sciences …
Filed under: Drug Treatment Washington D.C.
Under the worst case scenario of gridlock in Washington, D.C., some $ 600 billion in tax hikes and expenditure cuts will go into effect in early 2013. Under these circumstances a feeble U.S. … Data from study 102 revealed that Stribild was non …
Read more on Zacks.com
AARP Opposes Cost-Shifting to Seniors in Medicare and Medicaid
Filed under: Drug Treatment Washington D.C.
WASHINGTON, D.C. –(ENEWSPF)–November 20, 2012. Yesterday, AARP sent a letter to members of Congress and the President opposing proposed changes to … Towards that end, we have worked with both sides of the aisle to support key pieces of legislation …
Read more on eNews Park Forest
How do TB drugs interact with HIV drugs? – In January, 2012, the US Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease. The drug rifampin, used for treating TB, can lower levels of the HIV medicine efavirenz, so the FDA recommended that patients who weigh more than 50 kg (110 pounds) and who are taking both medications should get 30 percent larger doses of efavirenz (an increase from 600 mg to 800 mg). Now, a new analysis by conducted by researchers with the Adult AIDS Clinical Trials Group (ACTG) at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH) suggests this recommended dose adjustment may not be necessary, particularly in non-Caucasian populations. As described in a talk at the XIX International AIDS Conference in Washington, DC on Monday, July 23, 2012, the new FDA guidelines were based on several small studies in European TB patients and one in healthy volunteers, indicating a decrease in efavirenz levels with rifampin. The guidelines were also informed by a mathematical model, which showed that increasing efavirenz to 800 mg when given with rifampin would increase levels to those seen on the regular dose of 600 mg. These data may not apply to patients in African and Asian populations because of genetic differences that lead to higher efavirenz levels …